Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan.
Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, 1-78-1, Sho-machi, Tokushima 770-8505, Japan; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt; Department of Pharmaceutics, College of Pharmacy, Hail University, Hail 81442, Saudi Arabia.
Eur J Pharm Biopharm. 2018 Jun;127:142-149. doi: 10.1016/j.ejpb.2018.02.019. Epub 2018 Feb 17.
Surface decoration of liposomes with polyethylene glycol (PEG), PEGylation, is recognized as a method to bestow liposomes with a prolonged circulation time following intravenous administration. However, many reports have emphasized that a first dose of PEGylated liposomes (PL) elicits an anti-PEG IgM antibody response that can trigger a rapid systemic clearance of a second dose of PL via a phenomenon that is referred to as "accelerated blood clearance (ABC)." Such a phenomenon is usually observed with PL that has been modified with methoxy-PEG. In the current study, we introduced various functional groups, methoxy (OCH), amino (NH), carboxyl (COOH), and hydroxyl (OH), at the chain ends of PEG to investigate the effect on anti-PEG IgM induction. Among different PEG-modified liposomes, hydroxyl PEG-modified liposomes (PL-OH) efficiently attenuated the anti-PEG IgM response in vitro. In addition, PL-OH was less recognizable by anti-PEG IgM compared with other PLs. These findings raised the possibility that PL-OH could attenuate/abrogate elicitation of the ABC phenomenon. Nonetheless, upon repeated intravenous injection, PL-OH triggered the enhanced clearance of a subsequently injected second dose. Furthermore, in vitro studies have demonstrated that, as a complement activator, PL-OH is stronger than PL-OCH and induces further complement activation in the presence of anti-PEG IgM, which was the predominant contributor to the rapid clearance of a second dose of PL-OH. Our results suggest that the screening of complement activation by polymer-modified products in tandem with anti-polymer antibody production should be a prerequisite in the development of polymers that might enhance the therapeutic efficacy of nanocarriers.
脂质体表面用聚乙二醇(PEG)进行修饰,即 PEG 化,被认为是一种使脂质体在静脉给药后延长循环时间的方法。然而,许多报道强调,首次给予 PEG 化脂质体(PL)会引发抗 PEG IgM 抗体反应,通过一种称为“加速血液清除(ABC)”的现象,可迅速清除第二剂 PL。这种现象通常在经过甲氧基-PEG 修饰的 PL 中观察到。在本研究中,我们在 PEG 的链末端引入了各种官能团,甲氧基(OCH)、氨基(NH)、羧基(COOH)和羟基(OH),以研究其对诱导抗 PEG IgM 的影响。在不同的 PEG 修饰的脂质体中,羟基 PEG 修饰的脂质体(PL-OH)在体外有效地减弱了抗 PEG IgM 反应。此外,PL-OH 与其他 PL 相比,不易被抗 PEG IgM 识别。这些发现表明 PL-OH 可能减弱/消除 ABC 现象的发生。尽管如此,在重复静脉注射后,PL-OH 引发了随后注射的第二剂药物的增强清除。此外,体外研究表明,作为补体激活物,PL-OH 比 PL-OCH 更强,并在存在抗 PEG IgM 的情况下诱导进一步的补体激活,这是导致 PL-OH 第二剂快速清除的主要原因。我们的结果表明,在开发可能增强纳米载体治疗效果的聚合物时,应该在聚合物修饰产品的补体激活筛选与抗聚合物抗体产生方面进行并行研究,这应成为一个前提条件。